Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?
There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" including "antigen silencing", "tolerance" including "infectious tolerance" and "anergy" or "immunosuppression" have been identified in different model systems and all these could, in part, account for the lack of immune recognition in B cell lymphoma. Malignant B cells are poor antigen presenting cells and T cells in close proximity to the malignant cells are hyporesponsive with detects in T cell receptor signaling and cytotoxic effector function. This review will discuss recent in vitro findings in context of in vivo data in murine model systems relevant to B cell lymphoma. Understanding these complex defects of anti-lymphoma immune responses should allow us to redefine our immunotherapeutic strategies to overcome these detects and induce clinically sufficient T cell mediated immune responses.
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School Boston, MA 02115, USA. schultze@mbcrr.harvard.edu
J L
JL
Schultze
D000818:Animals; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology*